Home/Pipeline/RZQ-MM*

RZQ-MM*

Type 1 Diabetes

PreclinicalActive

Key Facts

Indication

Type 1 Diabetes

Phase

Preclinical

Status

Active

Company

Rezq Bio

About Rezq Bio

Rezq Bio is a private, preclinical-stage biotech founded in 2021, pioneering a localized immunomodulation platform using dendritic cell therapies. Its lead program, RZQ-MC1 for early-onset Type 1 Diabetes, has completed a Phase 1A safety trial and is preparing for Phase 1B/2A, supported by a pipeline targeting colitis and transplant support. The company is targeting a large, underserved market in autoimmune diseases, beginning with T1D, which lacks disease-modifying treatments and affects millions globally. Its approach differentiates by aiming to restore immune tolerance locally without systemic immunosuppression.

View full company profile

Therapeutic Areas

Autoimmune Diseases Inflammatory Diseases Type 1 Diabetes

Other Type 1 Diabetes Drugs

Drug	Company	Phase	Status
eRapa	Biodexa Pharmaceuticals	Preclinical	Research
ImmCelz™	Creative Medical Technology Holdings	Clinical Trial	Active
Adimune (ADi-001/002)	Aditxt	Preclinical / Early Clinical	Active
MSC‑Diabetes	Advancells	Phase 1	Active
BioChaperone® Lispro (THDB0206)	Adocia	Phase 3	Active
AdoShell® Islet Cell Therapy	Adocia	Preclinical	Platform Development
Pediatric Indications (<2 years)	Tandem Diabetes	Research	Exploratory
Icovamenib (BMF-219)	Biomea Fusion	Phase 2	Completed Follow-up, Data Pending
Undisclosed Novel Strategy	CG Scientific	Pre-clinical	Early Research
Sotagliflozin	Lexicon Pharmaceuticals	Phase 3	Regulatory Path Uncertain
Stem Cell-Derived Beta Cells	BioTalentum	Pre-clinical	Active
NICHE	Continuity Biosciences	Pre-clinical	Active